The results demonstrated that ALDH1A1 and PLK3 may serve as biomarkers to predict metastasis and the development of radio-resistance in prostate cancer patients and may represent potential therapeutic targets to eliminate metastatic cells [86]. Here, PLK3 is linked to prostate carcinoma.